Study of Semaglutide to Reduce Alcohol Use and Heart Disease Risk in Adults Living with HIV

What this Trial Is About

Researchers are studying whether the drug semaglutide can reduce alcohol consumption among adults living with HIV. The study aims to find out if semaglutide can lower the number of alcoholic drinks consumed per week, reduce the number of cigarettes smoked daily, and decrease the risk of cardiovascular disease in people with HIV who drink alcohol andor smoke tobacco. This trial is a Phase 2 randomized study comparing semaglutide to a placebo. Participants will take semaglutide or a placebo for three months. During this time, they will visit the clinic three times for checkups and tests. Researchers will collect blood, stool, and saliva samples to monitor changes and effects. The study uses a quadruple-masked design to ensure unbiased results. Throughout the study, participants will be monitored for alcohol and cigarette use, inflammation markers, and cardiovascular risk factors. The main outcome measured is the average number of drinks per week after three months. Additional assessments include average cigarettes smoked daily and systemic inflammation levels. Participants will be followed closely during the treatment period to track these health measures.

GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV